Applied BioCode Cash Flow Reinvestment Rate

Latest as of September 2022: 2.85x

Applied BioCode cash flow reinvestment rate. Applied BioCode (6598) has a Cash Flow Reinvestment Rate of 2.85x as of September 2022, reinvesting NT$18.11 Million (capex NT$12.00 Million plus investments NT$-6.11 Million) from operating cash flow of NT$6.35 Million. Explore cash flow to debt ratio of Applied BioCode to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

2.85x
(Capex + Investments) / Operating CF

Total Reinvested

NT$18.11 Million
Capex + Investments

Operating Cash Flow

NT$6.35 Million
TWD

Capital Expenditures

NT$12.00 Million
TWD

Cash Flow Reinvestment Rate of Applied BioCode (2022–2022)

Cash flow reinvestment rate of Applied BioCode from 2022 to 2022. Historical reinvestment intensity for Applied BioCode across 1 annual periods. Explore reinvestment intensity of Applied BioCode to see what proportion of operating cash flow is directed to capital expenditures.

Applied BioCode Cash Flow Reinvestment Rate by Year (2022–2022)

Applied BioCode cash flow reinvestment rate by year from 2022 to 2022. Year-by-year capital reinvestment analysis for Applied BioCode. For the full cash flow conversion analysis, see cash flow conversion of Applied BioCode.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2022 0.30x NT$44.28 Million NT$145.87 Million NT$22.14 Million —
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow